Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefepime
Drug ID BADD_D00386
Description Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
Indications and Usage For the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
Marketing Status approved; investigational
ATC Code J01DE01
DrugBank ID DB01413
KEGG ID D02376
MeSH ID D000077723
PubChem ID 5479537
TTD Drug ID D0A1CB
NDC Product Code 44567-130; 60505-6144; 60505-6146; 63323-326; 66794-209; 60505-6245; 66288-8100; 66794-210; 60505-6147; 82608-011; 44567-241; 60505-6246; 0338-1301; 44567-240; 63323-340; 10402-003; 52946-0919; 60505-6145; 0409-9735; 44567-131; 0409-9566; 66558-0204
UNII 807PW4VQE3
Synonyms Cefepime | Cefepim | Cefepime Hydrochloride | Maxipime | Axépim | Quadrocef | BMY 28142 | BMY-28142 | BMY28142
Chemical Information
Molecular Formula C19H24N6O5S2
CAS Registry Number 88040-23-7
SMILES C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Wheezing22.03.01.0090.000131%
White blood cell count13.01.06.027--Not Available
Mental status changes19.07.01.0010.000991%Not Available
Tubulointerstitial nephritis20.05.02.0020.000365%Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.000301%Not Available
General physical health deterioration08.01.03.0180.000073%Not Available
Blood phosphorus decreased13.11.01.015--Not Available
Cytokine release syndrome10.02.01.0100.000049%
Organ failure08.01.03.0410.000049%Not Available
Haemorrhage24.07.01.002--Not Available
Abdominal infection11.01.07.014; 07.19.02.007--
Muscle mass15.05.03.018--Not Available
Cognitive disorder17.03.03.003; 19.21.02.0010.000049%
Pulseless electrical activity02.03.04.0200.000049%Not Available
Vasodilation procedure25.03.01.001--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000049%Not Available
Coombs test positive13.01.01.002--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.000146%Not Available
Renal impairment20.01.03.0100.000204%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000073%Not Available
Chronic kidney disease20.01.03.0170.000107%
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Treatment failure08.06.01.0170.000097%Not Available
Acute kidney injury20.01.03.0160.004262%
Posterior reversible encephalopathy syndrome17.13.02.0070.000073%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000049%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021; 12.03.01.0640.000316%Not Available
Candida infection11.03.03.021--
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene